NCDB Adding New Quality Measures

The CoC National Cancer Database (NCDB) is adding four new quality measures in 2024, in addition to clinical updates to two existing quality measures. An official release date will be announced shortly, and accredited programs will be notified as to when the measure specifications can be accessed in the Rapid Cancer Reporting System (RCRS) library.

The new quality measures are as follows:

• For patients with any stage cervical cancer treated with primary radiation with curative intent, brachytherapy is used.
• For patients with low grade Ta bladder cancer undergoing transurethral resection of bladder tumor, intravesical chemotherapy* is administered within 24 hours of the procedure.

*chemotherapy within 24 hours of the transurethral resection assumed to be intravesical however the NCDB does not differentiate this from systemic chemotherapy

• For patients with low-risk prostate cancer (Gleason <= 6 and PSA < 10 and <= cT2), active surveillance is performed.
• For patients with surgically managed, cT1a kidney tumors, partial nephrectomy is performed.

The following quality measures are reflective of clinical updates:

• For patients <=75 years old with HER2+ or triple negative breast cancer with any clinical N > 0 or clinical T > 1, neoadjuvant chemotherapy and/or immunotherapy is initiated within 60 days of diagnosis, or recommended.
• For patients with surgically treated clinical T4NanyM0 or TanyN2M0 rectal cancer, neoadjuvant radiation therapy is initiated within 9 months prior to resection or recommended.